Introduction {#Sec1}
============

Computed tomography (CT) is an important diagnostic imaging modality that plays a key role in medical diagnosis. The number of CT examinations has shown a steady increase, and recent reports estimate that in the USA 62 million examinations per year are performed with an estimated growth of 8--10 % per year \[[@CR1], [@CR2]\]. In the USA, patient exposures associated with medical imaging have become the leading source of exposure of the population. In medical imaging, CT is the most important contributor to patient exposures \[[@CR1]--[@CR3]\].

In the European Union, member states are obliged to survey dose data following Article 12 of EU Directive 97/43/Euratom. The last evaluation of measured CT doses in the Netherlands was the "Demonstration Project Patient Dosimetry Radiology" (DP), which ran in 2001--2004 in 11 institutions, collecting specific data on 24 radiographic and 11 CT indications \[[@CR5]\]. In subsequent years, only rough estimations of population dose have been made based on the information on the number of CT studies and type of CT scans derived from yearly data collections of medical imaging practice in the Netherlands. A disadvantage was that these routine yearly data collections were based on financial billing codes and not on actual practical clinical CT protocols or on CT dose assessment; therefore, they only yielded basic data, limiting the usefulness for clinical practice or for feedback.

In the Netherlands in 2010, about 9.8 million diagnostic imaging studies were performed using ionising radiation. Of these, 1.16 million were CT studies, doubling the number compared to 2002 (Figure [1](#Fig1){ref-type="fig"}). The average dose to the Dutch population associated with medical imaging was estimated to be 0.89 milliSievert (mSv). CT\'s contribution to this dose was 0.42 mSv (47.5 %), while other big contributors were angiography and interventions (22.3 %), conventional radiography and mammography (17.6 %), and nuclear medicine (11.0 %) \[[@CR4]\]. Thus, while the above estimations were based on the actual number of diagnostic studies in 2010, the effective doses used for the estimations were taken from the DP study \[[@CR5]\].Fig. 1Trends in the number of CT examinations 1991--2010Fig. 2Box plots of the effective dose (mSv) of the three most frequently used CT protocols

This survey is similar in design to previous surveys performed in Germany \[[@CR6], [@CR7]\] and the UK \[[@CR8], [@CR9]\]. But in contrast to all but the newest UK survey, our protocols were based on the frequency of use in clinical practice, and new ICRP-103 conversion factors were used throughout.

The goal of the present survey was to renew the estimation of patient dose from multidetector CT and to improve the usefulness of the data for daily clinical practice by collecting dose data on the most frequently used CT protocols.

Materials and methods {#Sec2}
=====================

Hospital and CT protocol selection {#Sec3}
----------------------------------

For this CT dose survey, a set of 21 hospitals was selected randomly from all hospitals in the country with a balance among general hospitals, categorical hospitals, and academic hospitals.

In an initial phase, the CT practice in these 21 participating hospitals was surveyed for a few days. The observed practices resulted in a list of 21 CT protocols representing the CT examinations responsible for more than 90 % of the annual CT effective dose and more than 80 % of the number of CT exams done in the Netherlands (Table [1](#Tab1){ref-type="table"}). They formed the basis for the subsequent CT part of the National Survey on Radiation Dose (NSRD-CT).Table 1Dose results of CT protocols used in this national survey on CT radiation dosesProtocol nameClinical indicationRelative frequency (%)Median scan range (mm)Median (P75) DLP (mGy cm)Median (P75) E~103~ (mSv)Ratio max/min EBrainHaemorrhage23.8155813.7 (935.6)1.5 (1.8)3.3SinusSinusitis9.0116105.7 (133.4)0.2 (0.3)4.9NeckStandard2.3252329.9 (404.3)1.7 (2.1)2.2Neck-thorax-abdomenStandard0.7880985.1 (1,117.6)13.8 (15.6)1.7ThoraxStandard6.6313320.0 (346.5)4.6 (5.0)2.8Thorax-liverLung cancer4.1401542.0 (608.1)8.1 (9.1)2.7Thorax-abdomenStandard9.5687813.8 (885.7)11.6 (12.6)3.9Thorax HRInterstitial Dz3.1273142.8 (276.1)2.1 (4.0)13.4AbdomenStandard20.0441567.0 (618.0)8.0 (8.7)4.8Abdomen low-doseUrolithiasis2.1399301.6 (329.4)4.5 (4.9)3.3CT urographyHaematuria2.8452708.0 (981.6)10.0 (13.8)2.5Liver multiphasicLiver Tx1.14191,322.2 (1,496.6)19.4 (22.4)1.4Pancreas multiphasicAdeno ca0.6409899.0 (1,000.0)13.2 (14.7)2.0Kidney multiphasicRCC0.43811,166.5 (1,371.2)17.0 (20.2)3.1CT coronary angioCAD1.5125516.5 (671.4)13.5 (20.1)3.0CT pulmonary angioPE4.8279291.5 (371.0)4.2 (5.4)2.7CTA total aortaDissection0.7666822.5 (836.8)11.7 (11.9)1.1CTA abdominal aortaAAA1.8474555.5 (727.1)7.8 (10.3)3.8C-SpineStandard2.5213276.0 (320.9)1.4 (1.6)5.4L-SpineStandard1.5171308.2 (405.5)4.3 (5.7)3.2Bony pelvisStandard1.0223332.0 (382.1)4.3 (4.9)1.6*P75* 75th percentile, *DLP* dose length product, *E*~*103*~ effective dose according to ICRP-103, *Dz* disease, *Tx* transplantation, *ca* carcinoma, *RCC* renal cell cancer, *CAD* coronary artery disease, *PE* pulmonary embolism, *AAA* abdominal aortic aneurysm

Nationwide dose survey in CT {#Sec4}
----------------------------

Based on the methodology used in the prior demonstration project \[[@CR5]\], a Web survey was developed together with the data analysis department of the National Institute for Public Health and Environment RIVM (RIVM, Bilthoven, the Netherlands) from the Ministry of Health. A survey users\' guide was available to the participants, which included detailed protocol descriptions for guidance.

The hospitals were asked to complete a Web survey with detailed parameters for one standard-sized patient per protocol, including the dose length product (DLP) extracted from the scanner dose report. For all scan phases of each protocol, participants were required to record data on: (1) patient parameters \[sex, weight, length, body mass index (BMI)\], (2) scanner type and parameters of the scan technique \[tube voltage (kV), tube current (mA), rotation time\], and (3) type and settings of automatic exposure control (AEC) and tube current modulation \[TCM; noise index (NI), standard deviation (SD), or reference mean effective tube load (mAs)\].

Since the DLP was taken from the scanner dose report, overrange was taken into consideration. We studied local protocols for given clinical indications. In these local protocols, the kV could be variable per scan phase. Tube current modulation techniques were employed as defined in the local scan protocols.

Patient selection {#Sec5}
-----------------

As effective dose has only been defined for normal-sized patients, the average patient in the Netherlands \[[@CR10]\] with a margin ± 15 % was taken as a basis for patient selection. Therefore, patients were only used in the final dose analysis if their parameters were within the body weight range of 65.0--89.0 kg, body size of 1.61--1.87 m, and BMI of 21.6--29.2 kg/m^2^.

Radiation dose parameters and calculations {#Sec6}
------------------------------------------

Dose parameters such as (achieved) average effective mAs, volume CT dose index (CTDIvol), and dose-length product (DLP) were recorded for each scan phase from the dose report. Effective dose (E) was estimated by multiplying the DLP by recently established ICRP-103-based E/DLP coefficients for the relevant anatomical regions for multidetector CT (for 120 kV: head 0.0019; neck 0.0051; thorax 0.0145; abdomen 0.0153; pelvis 0.0129; for the weighted averages for multiregional scanning: neck-thorax 0.0134; thorax-abdomen 0.0149; abdomen-pelvis 0.0141; thorax-abdomen-pelvis 0.0142; neck-thorax-abdomen-pelvis 0.0138 \[[@CR11]\]). In comparison, values using ICRP-60 for 120 kV would have been: head 0.0016; neck 0.0057; thorax 0.0136; abdomen 0.0155; pelvis 0.0167. The weighted averages for multiregional scanning are: neck-thorax 0.0130; thorax-abdomen 0.0145; abdomen-pelvis 0.0161; thorax-abdomen-pelvis 0.0152; neck-thorax-abdomen-pelvis 0.0148 \[[@CR11]\]. No dosimetry measurements were performed on site.

### Multiregional scanning {#Sec7}

In multiregional scanning, given the clinical indication, the anatomy can be scanned in either one scan (1 phase scanning, 1P) or two separate scans (2 phase scanning, 2P). Table [2](#Tab2){ref-type="table"} lists those patients scanned in one phase and those in two separately. Differences in data come from differences in overranging and from the use of slightly different E/DLP conversion factors.Table 2Dose results of individual phases used in this National Survey on Radiation Doses in CTProtocol nameType scanningMedian scan range (mm)Median (P75) DLP (mGy cm)Median (P75) E~103~ (mSv)Ratio max/min EBrainS160806.0 (1,023.5)1.5 (1.9)3.3H146901.6 (918.6)1.7 (1.7)1.1SinusH116106.4 (136.3)0.2 (0.3)4.9NeckH252329.9 (404.3)1.7 (2.1)2.2Neck--thorax-abdomenH 1P872968.1 (985.1)16.2 (16.6)1.3H 2P Neck241280.0 (334.0)1.4 (1.7)1.5H 2P Tx-Abd648824.0 (850.0)11.7 (12.1)1.4ThoraxH313320.0 (346.5)4.6 (5.0)2.8Thorax-liverH 1P396383.0 (577.0)5.7 (8.6)2.3H 2P Tx320279.7 (300.8)4.1 (4.4)1.6H 2P Liver241277.4 (362.3)4.2 (5.5)2.1Thorax-abdomenH 1P630764.5 (970.0)10.9 (13.8)3.7H 2P Tx293279.1 (298.3)4.0 (4.3)4.6H 2P Abd437511.3 (551.1)7.2 (7.8)2.5Thorax HRS Insp27055.0 (55.0)0.8 (0.8)2.3S Exp1604.0 (4.5)0.1 (0.1)1.5H Insp318271.5 (378.4)3.9 (5.5)3.4H Exp30119.9 (30.3)0.3 (0.4)4.4AbdomenH Portal441567.0 (618.0)8.0 (8.7)4.8Abdomen low doseH Unenhanced399301.6 (329.4)4.5 (4.9)3.3CT urographyH Unenhanced412328.0 (404.3)4.6 (5.7)5.7H Nephrographic-excretory452490.3 (564.7)6.9 (8.0)1.8Liver multiphasicH Unenhanced240265.6 (308.0)4.1 (4.7)1.6H Arterial237337.0 (349.3)5.2 (5.3)2.0H Portal419490.0 (677.5)6.9 (9.6)2.3H Delayed237307.0 (372.2)4.7 (5.7)2.0Pancreas multiphasicH Unenhanced189193.0 (224.0)3.0 (3.4)2.7H Pancreatic180172.0 (242.0)2.6 (3.7)3.2H Portal409464.0 (509.6)6.5 (7.2)1.8Kidney multiphasicH Unenhanced231295.0 (346.3)4.3 (5.3)2.2H Corticomed202391.0 (538.5)5.7 (8.1)4.8H Nephrogenic381331.0 (351.0)4.9 (5.1)1.5H Excretory393616.0 (623.0)8.7 (8.8)1.8CT coronary angioS Calcium14048.1 (50.6)1.4 (1.5)1.6H Arterial125492.4 (622.1)14.8 (18.7)2.7CT pulmonary angioH Arterial279291.5 (371.0)4.2 (5.4)2.7CTA total aortaH Arterial666822.5 (836.8)11.7 (11.9)1.1CTA abdominal aortaH Arterial474555.5 (627.6)7.8 (8.8)2.0C-SpineH Unenhanced213276.0 (320.9)1.4 (1.6)5.4L-SpineH Unenhanced171308.2 (405.5)4.3 (5.7)3.2Bony pelvisH Unenhanced223332.0 (382.1)4.3 (4.9)1.6*P75* 75th percentile, *DLP* dose length product, *E*~*103*~ effective dose according to ICRP-103, *Dz* disease, *S* sequential, *H* helical, *1P* one phase, *2P* two phases, *Insp* inspiration, *Exp* expiration, *Tx* thorax, *Abd* abdomen

Data selection {#Sec8}
--------------

Outliers for CTDIvol and DLP were excluded as follows: for each protocol the median patient dose was calculated. Data that resulted in a calculated patient dose for a given protocol that was larger than five times the median value or smaller than 0.2 times the median value were regarded as a human report error and discarded from further data analysis. Exclusion of these outliers will influence the ratio between maximum and minimum E, but since we believe these to represent report errors, this exclusion may render the per protocol max/min E ratios more representative.

Statistical analysis {#Sec9}
--------------------

Box and whisker plots were used to visualise variations in the radiation dose parameters. These profiles were characterised by five parameters. The central line in the box represents the median value, the edges of the box the 25th percentile (P25) and 75th percentile, and the whiskers the minimum and maximum values. All calculations were performed with Excel 2011 for Mac (Microsoft, Redmond, WA, USA).

Results {#Sec10}
=======

In the intital practice survey phase, 5,017 studies were used to construct the protocol Top-21. The relative frequency figures of the Top-21 protocols are listed in Table [1](#Tab1){ref-type="table"}. The most frequently performed protocols were brain 23.8 %, abdomen 20.0 %, and thorax-abdomen 9.5 %.

From the 21 participating hospitals with an installed base of 30 scanners, 14 hospitals submitted complete and valid data for 186 standard-sized patients (247 scan phases) on 19 scanners. Each protocol was characterised using data of an average of nine scanners and an average of six hospitals per protocol were used for final analysis of effective CT doses of the 21 CT protocols. Three CT scanners were 4-row, five were 16-row, one was 40-row, eight were 64-row, and two were 128-row. Modern volumetric (3D) tube current modulation techniques were employed in all scanners, except for the four-row models. All image reconstruction was done using filtered back projection techniques.

For the standard-sized patients, the established median DLP and E doses ranged from a low of 105 mGy cm and 0.2 mSv for sinus CT to a high of 1322 mGy cm and 19.4 mSv for multiphasic liver CT (Table [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The most frequent examinations were brain, abdomen, and thorax-abdomen CT, which showed a modest median DLP of 814 mGy cm, 567 mGy cm, and 814 mGy cm, and median effective doses of 1.5 mSv, 8.0 mSv, and 11.6 mSv, respectively (Figure [2](#Fig2){ref-type="fig"}).

The highest doses are observed for multiphasic oncology CT protocols in the abdomen and for evaluation of tumours in the liver and kidney. These were scanned in three to four phases with a median DLP of 1,322 mGy cm and 1,167 mGy cm and corresponding median effective doses of 19.4 mSv and 17.0 mSv. Another relatively dose-intensive CT protocol is the lymphoma staging of the neck, thorax, and abdomen with median DLP of 985 mGy cm and E of 13.8 mSv.

For clinical indications in which contrast media timing is not critical (lymphoma staging), hospitals have decided to split long image ranges into two shorter helical acquisitions. The dose penalty of this practice is limited but variable (Table [2](#Tab2){ref-type="table"}): For imaging of the neck, thorax, and abdomen, the DLP is 1,104 mGy cm when the neck and thorax-abdomen are scanned separately versus 968 mGy cm for the neck-thorax-abdomen scanned in one run. In contrast, for imaging of the thorax and abdomen, the difference is only 790 mGy cm versus 769 mGy cm. Most differences lie in differences in the extra dose from overranging \[[@CR12], [@CR13]\]. In contrast, most of the dose increase is seen in imaging of the thorax and liver CT for lung carcinoma staging, with 557 mGy cm for the lung and liver scanned separately versus 383 mGy cm for the thorax-liver in one run. This is due to the fact that for the thorax a lower technique can be chosen.

Ratios between maximum and minimum effective dose ranged between 1.1 and 5.4 for most protocols, which is, although considerably variable between institutions, well within expected ranges seen in another survey \[[@CR9]\]. The incidental high figure for the ratio between the minimum and maximum protocol dose can largely be attributed to heterogeneity in examination techniques, such as when helical vs. sequential HRCT of the lungs are considered together as one protocol.

Comparison of our data with other CT dose surveys is given in Table [3](#Tab3){ref-type="table"}. Doses are lower than established in the German survey from 2001 \[[@CR6]\] and of comparable value to the results from the two most recent UK surveys \[[@CR8], [@CR9]\]. Additionally, when compared to older Dutch data \[[@CR5]\], all categories showed similar median values but lower mean values.Table 3Selected dose results of the national survey on radiation dose in CT and comparison with other studiesProtocol nameNSRD 2010 DLP (mGycm)NSRD 2010 E~103~ (mSv)Brix 2002; DLP (mGycm)Brix 2002 E~60~ (mSv)NRPB 2003 E~60~ (mGycm)HPA 2008 E~103~ (mSv)DP 2004 E~60~ (mSv)Brain813.71.51,0162.81.71.41.2Sinus105.70.22830.8----0.2Neck329.91.73022.0--3.0--Thorax320.04.63505.7--6.65.4Thorax-liver542.08.1----6.87.0--Thorax--abdomen813.811.61,02717.810.010.0--Thorax HR142.82.1----1.51.21.6Abdomen567.08.079014.47.86.77.7Abdomen low dose301.64.5------5.55.8CT Urography708.010.0------25.0--Liver multiphasic1,322.219.4------14.0--CT coronary angio516.513.558310.5--16.0--CT pulmonary angio291.54.23105.4--3.34.1CTA abdominal aorta555.57.855210.3--5.2--C-Spine276.01.42772.9--1.9--L-Spine308.24.34458.1--6.94.5Bony pelvis332.04.34408.2--6.0--*DLP* dose length product, *E*~*103*~ effective dose according to ICRP-103, *E*~*60*~ effective dose according to ICRP-60, *NSRD* this study, Brix 2002 = \[[@CR6]\]; NRPB 2003 = \[[@CR8]\]; HPA 2008 = \[[@CR9]\]; DP 2004 = \[[@CR5]\]

The Netherlands Commission on Radiation Dosimetry (NCRD) recently published diagnostic reference levels (DRL), including potentially achievable levels after strict dose optimisation \[[@CR14]\]. Comparison of our results with Dutch and other European DRLs \[[@CR8], [@CR15]--[@CR17]\] is given in Table [4](#Tab4){ref-type="table"}.Table 4P75 dose results of this study compared to adult DRL in CT across Europe and CanadaProtocol nameNSRD P75 DLP (mGy cm)NL 2012 DRL DLP (mGycm)NL 2012 achievable DLP (mGycm)F 2011 DRL DLP (mGycm)D 2010 DRL DLP (mGycm)UK 2003 DRL DLP (mGycm)CAN 2005 DRL DLP (mGycm)Brain935.6----1,0509509301,300Sinus133.4------100----Thorax346.5----475400--600Thorax-liver608.1--------580--Thorax-abdomen885.7----1,000--940--Thorax HR276.1--------170--Abdomen618.07004008009005601,100CT coronary angio671.41,000300\*--------CT pulmonary angio371.0350200--------L-Spine405.5----700500----Bony pelvis382.1------450----*P75* 75th percentile, *DRL* diagnostic reference level, *DLP* dose length product, *NSRD* this study, NL 2012 = \[[@CR14]\]; F 2011 = \[[@CR15]\]; D 2010 = \[[@CR16]\]; UK2003 = \[[@CR8]\]; CAN 2005 = \[[@CR17]\]

Discussion {#Sec11}
==========

The dosimetric results of this survey represent the clinical application of modern multidetector CT in the Netherlands. Compared to surrounding countries, relatively moderate doses are delivered for the most frequently performed CT examinations. This has not substantially changed compared to the Demonstration Project, which recorded data in 2001--2004 \[[@CR5]\].

In contrast to other surveys (except the one in Germany \[[@CR6]\]), we decided to gain data on a more specific level so that after data analysis we could give focussed feedback to the participating radiology departments. In the Netherlands many Radiology Information Systems only record billing codes (much fewer in number than the clinical scan protocols in practical use), and therefore asking detailed questions resulted in a relatively labour-intensive Web survey. In future surveys we hope to make use of dose reports directly from the CT scanners or from Hospital Information Systems.

It is not surprising that multiphasic abdominal tumour protocols generate the highest doses. CT urography (CTU), commonly regarded as dose intensive, was associated with a modest dose since only split-bolus two-phase studies were included. Using the data of CTU and renal cancer staging to estimate a single bolus, three-phase CTU with all phases covering the abdomen and pelvis would deliver a DLP in excess of 1,300 mGy cm.

In studies with similar clinical indications in which contrast medium administration was not critical, the dose effect of splitting long image ranges into two separate helical acquisitions was variable. The higher increase in thorax-liver CT is probably due to the difference in imaging requirements between thorax and liver, whereby a split protocol is better suitable to serve both most adequately. It should be noted that for different clinical indications in which contrast timing is critical, replacing two separate acquisitions with a combined acquisition may not be possible.

Our survey design is most comparable to the German survey by Brix et al. \[[@CR6]\]. The doses are lower than in that particular survey for almost all protocols. Compared to the data published by Shrimpton et al. \[[@CR8]\] and Wall et al. \[[@CR9]\] from the UK, which is one of the countries with the lowest CT doses worldwide, CT doses in the Netherlands are very similar.

It should be taken into account that we used the published E/DLP conversion factors derived using the ICRP-103 weighting factors \[[@CR11]\]. Use of ICRP-60 factors would change the results, but the level of change depends on the specific protocol. For equal DLP, head CT protocols would result in a 16 % lower effective dose, neck CT protocols in a 12 % higher effective dose, thorax CT protocols in a 7 % lower effective dose, abdomen CT protocols in an unchanged dose, and pelvic CT protocols in a 30 % higher dose (abdomen-pelvis 14 % higher).

The similarity in the data of this survey compared to its predecessor \[[@CR5]\] indicate, however, that during that period the more liberal use of CT and expansion of CT indications have been balanced with newer technology for dose optimisation such as volumetric tube current modulation and interactive collimation to reduce overranging.

Only a few hospitals in this small sample exceed the DLP set as the reference dose level for CT abdomen, but more than 25 % exceed the level set for CT pulmonary angiography. An integral part of this survey was feedback at the protocol level as a counterattack against this variability and lower doses nationwide. The best management strategy for this feedback will be a topic for future study.

Comparison of our data with other CT dose surveys is given in Table [3](#Tab3){ref-type="table"}. Doses are lower than established in the German survey from 2001 \[[@CR6]\] and of comparable value to the results from the two most recent UK surveys, published in reports NRPB-W67 \[[@CR8]\] and HPA-CRCE-12 \[[@CR9]\]. Additionally, when compared to older Dutch data \[[@CR5]\], all categories showed similar median values but lower mean values, indicating a trend to improvement in patient doses.

Comparison of the results of the survey with Dutch and other European DRLs \[[@CR8], [@CR15]--[@CR17]\] is given in Table [4](#Tab4){ref-type="table"}. The values of our DLP data are still above the achievable levels set in the Dutch DRL report \[[@CR14]\], indicating that the hospitals included in this pilot survey can improve patient dose by optimising their CT protocols and by upgrading to more dose-efficient hardware.

Obviously, the biggest drawback to the survey was the labour intensity of the Web survey for the participating hospitals. Therefore the response to this pilot was relatively limited and only two-thirds of hospitals participated. Second, there was an inherent lack of control of the data because manpower was limited to monitor data submission. While 14 hospitals submitted data, many entries were incomplete or partly invalid and not all hospitals contributed in the same way to all the protocols. Third, use of the effective dose is only defined for subjects with a normal BMI, and our results only apply to normal-sized or mildly obese patients. In slim patients and in patients with severe or malignant obesity, these results may vary proportionally.

In conclusion, in this CT part of the National Radiation Dose Survey, our detailed data show a moderate dose level in CT in comparison with surrounding countries, which has been stable over the past decade. The variability between hospitals indicates that there is still room for optimisation, whereby the details of our data may allow for more practical feedback than possible before.
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